Laboratory Total Operating Expenses vs Net Income From Continuing Ops Analysis
LH Stock | USD 207.67 1.52 0.74% |
Laboratory financial indicator trend analysis is infinitely more than just investigating Laboratory recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Laboratory is a good investment. Please check the relationship between Laboratory Total Operating Expenses and its Net Income From Continuing Ops accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
Total Operating Expenses vs Net Income From Continuing Ops
Total Operating Expenses vs Net Income From Continuing Ops Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Laboratory Total Operating Expenses account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Laboratory's Total Operating Expenses and Net Income From Continuing Ops is 0.45. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Laboratory of, assuming nothing else is changed. The correlation between historical values of Laboratory's Total Operating Expenses and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Laboratory of are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Total Operating Expenses i.e., Laboratory's Total Operating Expenses and Net Income From Continuing Ops go up and down completely randomly.
Correlation Coefficient | 0.45 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income From Continuing Ops
Most indicators from Laboratory's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Laboratory current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. As of now, Laboratory's Tax Provision is increasing as compared to previous years. The Laboratory's current Enterprise Value is estimated to increase to about 8.7 B, while Selling General Administrative is projected to decrease to under 1.1 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.6B | 4.4B | 3.1B | 1.9B | Total Revenue | 16.1B | 14.9B | 12.2B | 12.8B |
Laboratory fundamental ratios Correlations
Click cells to compare fundamentals
Laboratory Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Laboratory fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 98.6M | 98M | 97.5M | 91.6M | 87.6M | 96.0M | |
Total Assets | 18.0B | 20.1B | 20.4B | 20.2B | 16.7B | 17.6B | |
Other Current Liab | 942.4M | 1.4B | 1.4B | 1.1B | 804M | 502.9M | |
Total Current Liabilities | 1.9B | 2.6B | 3.1B | 2.8B | 3.2B | 3.4B | |
Total Stockholder Equity | 7.6B | 9.4B | 10.3B | 10.1B | 7.9B | 8.3B | |
Property Plant And Equipment Net | 2.6B | 2.7B | 2.8B | 3.0B | 2.9B | 3.1B | |
Net Debt | 6.7B | 5.4B | 4.9B | 5.9B | 5.4B | 5.7B | |
Retained Earnings | 7.9B | 9.4B | 10.5B | 10.6B | 7.9B | 8.3B | |
Accounts Payable | 632.3M | 638.9M | 621.3M | 934.8M | 827.5M | 868.9M | |
Cash | 337.5M | 1.3B | 1.5B | 430M | 536.8M | 290.8M | |
Non Current Assets Total | 15.0B | 14.9B | 15.1B | 15.5B | 13.0B | 13.6B | |
Non Currrent Assets Other | 435.4M | 410M | 462.6M | 432.7M | 536.5M | 270.8M | |
Cash And Short Term Investments | 337.5M | 1.3B | 1.5B | 430M | 536.8M | 299.7M | |
Net Receivables | 2.0B | 3.0B | 3.0B | 3.0B | 2.1B | 2.2B | |
Liabilities And Stockholders Equity | 18.0B | 20.1B | 20.4B | 20.2B | 16.7B | 17.6B | |
Non Current Liabilities Total | 7.8B | 7.6B | 7.3B | 7.0B | 5.6B | 3.1B | |
Other Current Assets | 373.7M | 364.8M | 478.1M | 707M | 655.3M | 688.1M | |
Other Stockholder Equity | 26.8M | 110.3M | (192M) | (493.2M) | 38.4M | 36.5M | |
Total Liab | 10.5B | 10.7B | 10.1B | 10.1B | 8.8B | 9.3B | |
Total Current Assets | 3.0B | 5.1B | 5.3B | 4.6B | 3.8B | 4.0B | |
Short Long Term Debt Total | 7.1B | 6.8B | 6.3B | 6.3B | 6.0B | 6.3B | |
Intangible Assets | 4.0B | 4.0B | 3.7B | 3.9B | 3.3B | 2.0B | |
Short Term Debt | 621.1M | 575.4M | 199M | 492.8M | 1.2B | 1.2B | |
Inventory | 244.7M | 423.2M | 401.4M | 470.6M | 474.6M | 498.3M | |
Property Plant And Equipment Gross | 2.6B | 2.7B | 5.2B | 5.7B | 5.8B | 6.1B | |
Accumulated Other Comprehensive Income | (372.4M) | (161.9M) | (192M) | (493.2M) | (59.3M) | (62.3M) | |
Other Liab | 1.3B | 1.4B | 1.2B | 1.1B | 1.2B | 702.7M | |
Other Assets | 356.5M | 350.9M | 484.2M | 440.3M | 506.3M | 531.7M | |
Long Term Debt | 5.8B | 5.4B | 5.4B | 5.0B | 4.1B | 3.1B | |
Property Plant Equipment | 2.7B | 2.8B | 2.8B | 3.0B | 3.4B | 3.6B | |
Good Will | 7.9B | 7.8B | 8.0B | 8.1B | 6.1B | 4.4B | |
Current Deferred Revenue | 451M | 506.5M | 558.5M | 582.1M | 421.7M | 442.8M | |
Net Tangible Assets | (4.3B) | (2.4B) | (1.4B) | (2.0B) | (1.8B) | (1.9B) | |
Long Term Debt Total | 5.9B | 5.5B | 5.5B | 5.1B | 5.9B | 4.8B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.123 | Dividend Share 2.88 | Earnings Share 4.68 | Revenue Per Share 142.986 | Quarterly Revenue Growth 0.046 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.